{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:05:43Z","timestamp":1793642743334,"version":"4.5.1"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100012727","name":"Institut universitaire de cardiologie et de pneumologie de Qu\u00e9bec, Universit\u00e9 Laval","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012727","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012727","name":"Institut universitaire de cardiologie et de pneumologie de Qu\u00e9bec, Universit\u00e9 Laval","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012727","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.bcp.2020.114112","type":"journal-article","created":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T00:27:37Z","timestamp":1593217657000},"page":"114112","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":77,"special_numbering":"C","title":["The management of severe asthma in 2020"],"prefix":"10.1016","volume":"179","author":[{"given":"Andr\u00e9anne","family":"C\u00f4t\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krystelle","family":"Godbout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis-Philippe","family":"Boulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2020.114112_b0005","doi-asserted-by":"crossref","unstructured":"B.E. Chipps, R.S. Zeiger, L. Borish, S.E. Wenzel, A. Yegin, M.L. Hayden, D.P. Miller, E.R. Bleecker, F.E.R. Simons, S.J. Szefler, S.T. Weiss, T. Haselkorn, T.S. Group, Key findings and clinical implications from The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study, The Journal of allergy and clinical immunology 130(2) (2012) 332-42.e10.","DOI":"10.1016\/j.jaci.2012.04.014"},{"issue":"Suppl","key":"10.1016\/j.bcp.2020.114112_b0010","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1513\/AnnalsATS.201309-307AW","article-title":"Clinical heterogeneity in the severe asthma research program","volume":"10","author":"Moore","year":"2013","journal-title":"Ann. Am. Thoracic Soc."},{"issue":"1","key":"10.1016\/j.bcp.2020.114112_b0015","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1600-065X.2011.01032.x","article-title":"Human asthma phenotypes: from the clinic, to cytokines, and back again","volume":"242","author":"Bhakta","year":"2011","journal-title":"Immunol. Rev."},{"issue":"1","key":"10.1016\/j.bcp.2020.114112_b0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MCP.0000000000000444","article-title":"The road to precision medicine in asthma: challenges and opportunities","volume":"24","author":"Hanania","year":"2018","journal-title":"Curr. Opin. Pulmonary Med."},{"key":"10.1016\/j.bcp.2020.114112_b0025","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s41030-016-0017-z","article-title":"Identification of Asthma Subtypes Using Clustering Methodologies","volume":"2","author":"Deliu","year":"2016","journal-title":"Pulm. Ther."},{"issue":"5","key":"10.1016\/j.bcp.2020.114112_b0030","first-page":"491","article-title":"Diagnosis and investigation in the severe asthma clinic","volume":"10","author":"Wark","year":"2016","journal-title":"Exp. Rev. Res. Med."},{"key":"10.1016\/j.bcp.2020.114112_b0035","doi-asserted-by":"crossref","unstructured":"S.D. Aaron, K.L. Vandemheen, J.M. FitzGerald, M. Ainslie, S. Gupta, C. Lemi\u00e8re, S.K. Field, R.A. McIvor, P. Hernandez, I. Mayers, S. Mulpuru, G.G. Alvarez, S. Pakhale, R. Mallick, L.-P. Boulet, N. Canadian Respiratory Research, Reevaluation of Diagnosis in Adults With Physician-Diagnosed Asthma, JAMA 317(3) (2017) 269-279.","DOI":"10.1001\/jama.2016.19627"},{"issue":"3","key":"10.1016\/j.bcp.2020.114112_b0040","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3121\/cmr.2.3.155","article-title":"Categorizing asthma severity: an overview of national guidelines","volume":"2","author":"Colice","year":"2004","journal-title":"Clin Med Res"},{"key":"10.1016\/j.bcp.2020.114112_b0045","unstructured":"Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2019. www.ginasthma.org. (Accessed 2019-05-31 2019)."},{"key":"10.1016\/j.bcp.2020.114112_b0050","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.201910-1934CI","article-title":"Optimal Asthma Control: Time for a New Target","author":"Beasley","year":"2020","journal-title":"Am. J. Respir. Crit Care Med."},{"key":"10.1016\/j.bcp.2020.114112_b0055","doi-asserted-by":"crossref","unstructured":"\u201cInternational ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma.\u201d Kian Fan Chung, Sally E. Wenzel, Jan L. Brozek, Andrew Bush, Mario Castro, Peter J. Sterk, Ian M. Adcock, Eric D. Bateman, Elisabeth H. Bel, Eugene R. Bleecker, Louis-Philippe Boulet, Christopher Brightling, Pascal Chanez, Sven-Erik Dahlen, Ratko Djukanovic, Urs Frey, Mina Gaga, Peter Gibson, Qutayba Hamid, Nizar N. Jajour, Thais Mauad, Ronald L. Sorkness and W. Gerald Teague. Eur Respir J 2014; 43: 343-373, The European respiratory journal 52(1) (2018).","DOI":"10.1183\/13993003.52020-2013"},{"issue":"4","key":"10.1016\/j.bcp.2020.114112_b0060","first-page":"199","article-title":"Recognition and management of severe asthma: A Canadian Thoracic Society position statement","volume":"1","author":"FitzGerald","year":"2017","journal-title":"Canadian J. Respir. Crit. Care, Sleep Med."},{"key":"10.1016\/j.bcp.2020.114112_b0065","unstructured":"C.J.t. 2020, Statistics Canada, Table 13-10-0096-08 Asthma, by age group."},{"key":"10.1016\/j.bcp.2020.114112_b0070","unstructured":"Center for Disease Control and Prevention, https:\/\/www.cdc.gov\/asthma\/asthmadata.htm (consulted Jan 26th 2020)."},{"issue":"4","key":"10.1016\/j.bcp.2020.114112_b0075","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jaci.2014.08.042","article-title":"The prevalence of severe refractory asthma","volume":"135","author":"Hekking","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"issue":"3","key":"10.1016\/j.bcp.2020.114112_b0080","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1136\/thoraxjnl-2015-207530","article-title":"The natural history of severe asthma and influences of early risk factors: a population-based cohort study","volume":"71","author":"Chen","year":"2016","journal-title":"Thorax"},{"issue":"3","key":"10.1016\/j.bcp.2020.114112_b0085","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00765-2017","article-title":"\u201cI have lost in every facet of my life\u201d: the hidden burden of severe asthma","volume":"50","author":"Foster","year":"2017","journal-title":"Eur. Resp. J."},{"issue":"2","key":"10.1016\/j.bcp.2020.114112_b0090","first-page":"74","article-title":"Direct health care costs associated with asthma in British Columbia","volume":"17","author":"Sadatsafavi","year":"2010","journal-title":"Can. Respir. J."},{"issue":"1","key":"10.1016\/j.bcp.2020.114112_b0095","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-022506","article-title":"Large care gaps in primary care management of asthma: a longitudinal practice audit","volume":"9","author":"Price","year":"2019","journal-title":"BMJ Open"},{"issue":"6","key":"10.1016\/j.bcp.2020.114112_b0100","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/j.1440-1843.2011.02012.x","article-title":"How to set up a severe asthma service","volume":"16","author":"McDonald","year":"2011","journal-title":"Respirology"},{"key":"10.1016\/j.bcp.2020.114112_b0105","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2147\/JAA.S178927","article-title":"Approaches to the assessment of severe asthma: barriers and strategies","volume":"12","author":"Majellano","year":"2019","journal-title":"J. Asthma Allergy"},{"issue":"19","key":"10.1016\/j.bcp.2020.114112_b0110","first-page":"31022","article-title":"Trajectory Analyses of Adherence Patterns in a Real-Life Moderate to Severe Asthma Population","volume":"S2213\u20132198","author":"van Boven","year":"2019","journal-title":"J. Allergy Clinic. Immunol. Pract."},{"issue":"1","key":"10.1016\/j.bcp.2020.114112_b0115","article-title":"Confounders of severe asthma: diagnoses to consider when asthma symptoms persist despite optimal therapy","volume":"11","author":"Gherasim","year":"2018","journal-title":"World Allergy Org. J."},{"issue":"1","key":"10.1016\/j.bcp.2020.114112_b0120","doi-asserted-by":"crossref","first-page":"00024","DOI":"10.1183\/23120541.00024-2015","article-title":"Management of the patient with eosinophilic asthma: a new era begins","volume":"1","author":"de Groot","year":"2015","journal-title":"ERJ Open Res."},{"issue":"4","key":"10.1016\/j.bcp.2020.114112_b0125","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1183\/09031936.00121308","article-title":"Influence of comorbid conditions on asthma","volume":"33","author":"Boulet","year":"2009","journal-title":"Eur. Respir. J."},{"issue":"7","key":"10.1016\/j.bcp.2020.114112_b0130","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1111\/resp.13134","article-title":"Multidimensional assessment of severe asthma: A systematic review and meta-analysis","volume":"22","author":"Clark","year":"2017","journal-title":"Respirology (Carlton, Vic.)"},{"issue":"2","key":"10.1016\/j.bcp.2020.114112_b0135","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1183\/09031936.00216013","article-title":"The clinical and genetic features of COPD-asthma overlap syndrome","volume":"44","author":"Hardin","year":"2014","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.bcp.2020.114112_b0140","article-title":"Asthma-COPD overlap syndrome: pathogenesis, clinical features, and therapeutic targets","volume":"358","author":"Leung","year":"2017","journal-title":"BMJ (Clinical research ed.)"},{"key":"10.1016\/j.bcp.2020.114112_b0145","first-page":"1443","article-title":"Clinical characteristics of the asthma-COPD overlap syndrome\u2013a systematic review","volume":"10","author":"Nielsen","year":"2015","journal-title":"Int. J. Chronic Obstr. Pulmonary Dis."},{"issue":"7","key":"10.1016\/j.bcp.2020.114112_b0150","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1136\/thoraxjnl-2014-206740","article-title":"Asthma-COPD overlap 2015: now we are six","volume":"70","author":"Gibson","year":"2015","journal-title":"Thorax"},{"issue":"5","key":"10.1016\/j.bcp.2020.114112_b0155","doi-asserted-by":"crossref","first-page":"1700068","DOI":"10.1183\/13993003.00068-2017","article-title":"Algorithm for identification of asthma-COPD overlap: consensus between the Spanish COPD and asthma guidelines","volume":"49","author":"Miravitlles","year":"2017","journal-title":"Eur. Respir. J."},{"issue":"3","key":"10.1016\/j.bcp.2020.114112_b0160","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1183\/13993003.00436-2016","article-title":"What is asthma-COPD overlap syndrome? Towards a consensus definition from a round table discussion","volume":"48","author":"Sin","year":"2016","journal-title":"Eur. Respir. J."},{"issue":"4","key":"10.1016\/j.bcp.2020.114112_b0165","first-page":"222","article-title":"CTS position statement: Pharmacotherapy in patients with COPD\u2014An update","volume":"1","author":"Bourbeau","year":"2017","journal-title":"Canadian J. Respir. Crit. Care Sleep Med."},{"issue":"3","key":"10.1016\/j.bcp.2020.114112_b0170","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1164\/rccm.200711-1754OC","article-title":"Cluster analysis and clinical asthma phenotypes","volume":"178","author":"Haldar","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.bcp.2020.114112_b0175","doi-asserted-by":"crossref","unstructured":"W.C. Moore, A.T. Hastie, X. Li, H. Li, W.W. Busse, N.N. Jarjour, S.E. Wenzel, S.P. Peters, D.A. Meyers, E.R. Bleecker, L. National Heart, P. Blood Institute's Severe Asthma Research, Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis, The Journal of allergy and clinical immunology 133(6) (2014) 1557-63.e5.","DOI":"10.1016\/j.jaci.2013.10.011"},{"key":"10.1016\/j.bcp.2020.114112_b0180","unstructured":"D. Lefaudeux, B. De Meulder, M.J. Loza, N. Peffer, A. Rowe, F. Baribaud, A.T. Bansal, R. Lutter, A.R. Sousa, J. Corfield, I. Pandis, P.S. Bakke, M. Caruso, P. Chanez, S.-E. Dahl\u00e9n, L.J. Fleming, S.J. Fowler, I. Horvath, N. Krug, P. Montuschi, M. Sanak, T. Sandstrom, D.E. Shaw, F. Singer, P.J. Sterk, G. Roberts, I.M. Adcock, R. Djukanovic, C. Auffray, K.F. Chung, U.B.S. Group, U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics, The Journal of allergy and clinical immunology 139(6) (2017) 1797-1807."},{"issue":"12","key":"10.1016\/j.bcp.2020.114112_b0185","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1164\/rccm.201406-1099OC","article-title":"Gene expression in relation to exhaled nitric oxide identifies novel asthma phenotypes with unique biomolecular pathways","volume":"190","author":"Modena","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"5","key":"10.1016\/j.bcp.2020.114112_b0190","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/nm.2678","article-title":"Asthma phenotypes: the evolution from clinical to molecular approaches","volume":"18","author":"Wenzel","year":"2012","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.bcp.2020.114112_b0195","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.pupt.2013.07.003","article-title":"Complex phenotypes in asthma: current definitions","volume":"26","author":"Wenzel","year":"2013","journal-title":"Pulm. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.bcp.2020.114112_b0200","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1164\/ajrccm.160.3.9812110","article-title":"Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics","volume":"160","author":"Wenzel","year":"1999","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.bcp.2020.114112_b0205","doi-asserted-by":"crossref","unstructured":"L. Borish, The immunology of asthma: Asthma phenotypes and their implications for personalized treatment, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 117(2) (2016) 108-114.","DOI":"10.1016\/j.anai.2016.04.022"},{"issue":"10","key":"10.1016\/j.bcp.2020.114112_b0210","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1056\/NEJMra1608969","article-title":"Severe and Difficult-to-Treat Asthma in Adults","volume":"377","author":"Israel","year":"2017","journal-title":"New England J. Med."},{"issue":"1","key":"10.1016\/j.bcp.2020.114112_b0215","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jaci.2017.04.009","article-title":"Oral corticosteroid exposure and adverse effects in asthmatic patients","volume":"141","author":"Sullivan","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"issue":"2","key":"10.1016\/j.bcp.2020.114112_b0220","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1183\/09031936.00075614","article-title":"Medication adherence and the risk of severe asthma exacerbations: a systematic review","volume":"45","author":"Engelkes","year":"2015","journal-title":"Eur. Res. J."},{"issue":"2","key":"10.1016\/j.bcp.2020.114112_b0225","first-page":"163","article-title":"Evolving phenotypes to endotypes: is precision medicine achievable in asthma?","volume":"14","author":"Bagnasco","year":"2020","journal-title":"Exp. Rev. Res. Med."},{"issue":"23","key":"10.1016\/j.bcp.2020.114112_b0230","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1056\/NEJMsb1503104","article-title":"Precision medicine\u2013personalized, problematic, and promising","volume":"372","author":"Jameson","year":"2015","journal-title":"New England J. Med."},{"key":"10.1016\/j.bcp.2020.114112_b0235","first-page":"1901509","article-title":"Targeting Treatable Traits in Severe Asthma A Randomised Controlled Trial","author":"McDonald","year":"2019","journal-title":"Eur. Res. J."},{"issue":"2","key":"10.1016\/j.bcp.2020.114112_b0240","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1183\/13993003.01359-2015","article-title":"Treatable traits: toward precision medicine of chronic airway diseases","volume":"47","author":"Agusti","year":"2016","journal-title":"Eur. Res. J."},{"key":"10.1016\/j.bcp.2020.114112_b0245","unstructured":"Global Initiative for Asthma, www.ginasthma.org (2019) 1-134."},{"issue":"1","key":"10.1016\/j.bcp.2020.114112_b0250","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00588-2019","article-title":"Management of severe asthma: a European Respiratory Society\/American Thoracic Society guideline","volume":"55","author":"Holguin","year":"2020","journal-title":"Eur. Res. J."},{"issue":"2","key":"10.1016\/j.bcp.2020.114112_b0255","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1067\/mai.2001.117880","article-title":"Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma","volume":"108","author":"Busse","year":"2001","journal-title":"J. Allergy Clin. Immunol."},{"issue":"2","key":"10.1016\/j.bcp.2020.114112_b0260","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1183\/09031936.01.00092101","article-title":"The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics","volume":"18","author":"Sol\u00e8r","year":"2001","journal-title":"Eur. Resp. J."},{"key":"10.1016\/j.bcp.2020.114112_b0265","doi-asserted-by":"crossref","unstructured":"R. Normansell, S. Walker, S.J. Milan, E.H. Walters, P. Nair, Omalizumab for asthma in adults and children, The Cochrane database of systematic reviews (1) (2014) CD003559-CD003559.","DOI":"10.1002\/14651858.CD003559.pub4"},{"key":"10.1016\/j.bcp.2020.114112_b0270","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.rmed.2019.02.003","article-title":"Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma","volume":"150","author":"Katsaounou","year":"2019","journal-title":"Respir. Med."},{"issue":"4","key":"10.1016\/j.bcp.2020.114112_b0275","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jaci.2016.02.027","article-title":"Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses","volume":"138","author":"Gauvreau","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"issue":"2","key":"10.1016\/j.bcp.2020.114112_b0280","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/rr41","article-title":"Th2 cytokines and asthma. The role of interleukin-5 in allergic eosinophilic disease","volume":"2","author":"Greenfeder","year":"2001","journal-title":"Respir. Res."},{"issue":"10","key":"10.1016\/j.bcp.2020.114112_b0285","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1056\/NEJMoa0805435","article-title":"Mepolizumab for prednisone-dependent asthma with sputum eosinophilia","volume":"360","author":"Nair","year":"2009","journal-title":"New England J. Med."},{"issue":"13","key":"10.1016\/j.bcp.2020.114112_b0290","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"New England J. Med."},{"issue":"13","key":"10.1016\/j.bcp.2020.114112_b0295","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"New England J. Med."},{"issue":"9842","key":"10.1016\/j.bcp.2020.114112_b0300","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet (London, England)"},{"issue":"10","key":"10.1016\/j.bcp.2020.114112_b0305","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1164\/rccm.201103-0396OC","article-title":"Res-5- Study, Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study","volume":"184","author":"Castro","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"4","key":"10.1016\/j.bcp.2020.114112_b0310","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.chest.2016.03.032","article-title":"Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels: A Randomized Phase 3 Study","volume":"150","author":"Bjermer","year":"2016","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.bcp.2020.114112_b0315","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.chest.2016.03.018","article-title":"Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma: Effects Across a Broad Range of Eosinophil Counts","volume":"150","author":"Corren","year":"2016","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.bcp.2020.114112_b0320","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet. Res. Med."},{"issue":"1","key":"10.1016\/j.bcp.2020.114112_b0325","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1164\/rccm.201707-1323OC","article-title":"Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab","volume":"197","author":"Mukherjee","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"10056","key":"10.1016\/j.bcp.2020.114112_b0330","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b2(2)-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial, Lancet","volume":"388","author":"Bleecker","year":"2016","journal-title":"(London, England)"},{"issue":"10056","key":"10.1016\/j.bcp.2020.114112_b0335","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"C.s. investigators, Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial, Lancet","volume":"388","author":"FitzGerald","year":"2016","journal-title":"(London, England)"},{"issue":"11","key":"10.1016\/j.bcp.2020.114112_b0340","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S2213-2600(14)70201-2","article-title":"Benralizumab, an anti-interleukin 5 receptor \u03b1 monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study","volume":"2","author":"Castro","year":"2014","journal-title":"Lancet. Res. Med."},{"issue":"25","key":"10.1016\/j.bcp.2020.114112_b0345","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma","volume":"376","author":"Nair","year":"2017","journal-title":"New England J. Med."},{"issue":"1","key":"10.1016\/j.bcp.2020.114112_b0350","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S2213-2600(18)30406-5","article-title":"Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial","volume":"7","author":"Busse","year":"2019","journal-title":"Lancet Respir. Med."},{"issue":"10","key":"10.1016\/j.bcp.2020.114112_b0355","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/j.clinthera.2019.07.007","article-title":"Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study","volume":"41","author":"Khurana","year":"2019","journal-title":"Clin. Ther."},{"issue":"9","key":"10.1016\/j.bcp.2020.114112_b0360","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1016\/j.clinthera.2016.07.010","article-title":"Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center Open-label, Phase IIIb Study","volume":"38","author":"Lugogo","year":"2016","journal-title":"Clin. Ther."},{"issue":"26","key":"10.1016\/j.bcp.2020.114112_b0365","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"New England J. Med."},{"issue":"26","key":"10.1016\/j.bcp.2020.114112_b0370","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma","volume":"378","author":"Castro","year":"2018","journal-title":"New England J. Med."},{"issue":"5","key":"10.1016\/j.bcp.2020.114112_b0375","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s12325-018-0702-4","article-title":"Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy\/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma","volume":"35","author":"Busse","year":"2018","journal-title":"Adv. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2020.114112_b0380","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12931-019-1138-3","article-title":"Monoclonal antibodies in type 2 asthma: a systematic review and network meta-analysis","volume":"20","author":"Edris","year":"2019","journal-title":"Respir. Res."},{"issue":"10","key":"10.1016\/j.bcp.2020.114112_b0385","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1056\/NEJMoa1704064","article-title":"Tezepelumab in Adults with Uncontrolled Asthma","volume":"377","author":"Corren","year":"2017","journal-title":"New England J. Med."},{"issue":"6","key":"10.1016\/j.bcp.2020.114112_b0390","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.jaci.2008.09.028","article-title":"Azithromycin or montelukast as inhaled corticosteroid-sparing agents in moderate-to-severe childhood asthma study","volume":"122","author":"Strunk","year":"2008","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.bcp.2020.114112_b0395","doi-asserted-by":"crossref","unstructured":"D.L. Hahn, M. Grasmick, S. Hetzel, S. Yale, A.S. Group, Azithromycin for bronchial asthma in adults: an effectiveness trial, J Am Board Fam Med 25(4) (2012) 442-459.","DOI":"10.3122\/jabfm.2012.04.110309"},{"issue":"4","key":"10.1016\/j.bcp.2020.114112_b0400","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1136\/thoraxjnl-2012-202698","article-title":"Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial","volume":"68","author":"Brusselle","year":"2013","journal-title":"Thorax"},{"issue":"10095","key":"10.1016\/j.bcp.2020.114112_b0405","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)31281-3","article-title":"Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Gibson","year":"2017","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.bcp.2020.114112_b0410","doi-asserted-by":"crossref","unstructured":"K.M. Kew, K. Dahri, Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA\/ICS) versus LABA\/ICS for adults with asthma, The Cochrane database of systematic reviews (1) (2016) CD011721-CD011721.","DOI":"10.1002\/14651858.CD011721.pub2"},{"issue":"2","key":"10.1016\/j.bcp.2020.114112_b0415","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1378\/chest.14-1698","article-title":"What is the role of tiotropium in asthma?: a systematic review with meta-analysis","volume":"147","author":"Rodrigo","year":"2015","journal-title":"Chest"},{"key":"10.1016\/j.bcp.2020.114112_b0420","doi-asserted-by":"crossref","unstructured":"M.E. Wechsler, M. Laviolette, A.S. Rubin, J. Fiterman, J.R. Lapa e Silva, P.L. Shah, E. Fiss, R. Olivenstein, N.C. Thomson, R.M. Niven, I.D. Pavord, M. Simoff, J.B. Hales, C. McEvoy, D.-J. Slebos, M. Holmes, M.J. Phillips, S.C. Erzurum, N.A. Hanania, K. Sumino, M. Kraft, G. Cox, D.H. Sterman, K. Hogarth, J.N. Kline, A.H. Mansur, B.E. Louie, W.M. Leeds, R.G. Barbers, J.H.M. Austin, N.S. Shargill, J. Quiring, B. Armstrong, M. Castro, G. Asthma Intervention Research 2 Trial Study, Bronchial thermoplasty: Long-term safety and effectiveness in patients with severe persistent asthma, The Journal of allergy and clinical immunology 132(6) (2013) 1295-1302.","DOI":"10.1016\/j.jaci.2013.08.009"},{"key":"10.1016\/j.bcp.2020.114112_b0425","doi-asserted-by":"crossref","unstructured":"M. Castro, A. Rubin, M. Laviolette, N.A. Hanania, B. Armstrong, G. Cox, A.I.R.T.S. Group, Persistence of effectiveness of bronchial thermoplasty in patients with severe asthma, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 107(1) (2011) 65-70.","DOI":"10.1016\/j.anai.2011.03.005"},{"key":"10.1016\/j.bcp.2020.114112_b0430","doi-asserted-by":"crossref","unstructured":"M. Castro, A.S. Rubin, M. Laviolette, J. Fiterman, M. De Andrade Lima, P.L. Shah, E. Fiss, R. Olivenstein, N.C. Thomson, R.M. Niven, I.D. Pavord, M. Simoff, D.R. Duhamel, C. McEvoy, R. Barbers, N.H.T. Ten Hacken, M.E. Wechsler, M. Holmes, M.J. Phillips, S. Erzurum, W. Lunn, E. Israel, N. Jarjour, M. Kraft, N.S. Shargill, J. Quiring, S.M. Berry, G. Cox, A.I.R.T.S. Group, Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial, American journal of respiratory and critical care medicine 181(2) (2010) 116-124.","DOI":"10.1164\/rccm.200903-0354OC"},{"key":"10.1016\/j.bcp.2020.114112_b0435","doi-asserted-by":"crossref","unstructured":"G. Cox, N.C. Thomson, A.S. Rubin, R.M. Niven, P.A. Corris, H.C. Siersted, R. Olivenstein, I.D. Pavord, D. McCormack, R. Chaudhuri, J.D. Miller, M. Laviolette, A.I.R.T.S. Group, Asthma control during the year after bronchial thermoplasty, The New England journal of medicine 356(13) (2007) 1327-1337.","DOI":"10.1056\/NEJMoa064707"},{"key":"10.1016\/j.bcp.2020.114112_b0440","doi-asserted-by":"crossref","unstructured":"I.D. Pavord, G. Cox, N.C. Thomson, A.S. Rubin, P.A. Corris, R.M. Niven, K.F. Chung, M. Laviolette, R.T.S. Group, Safety and efficacy of bronchial thermoplasty in symptomatic, severe asthma, American journal of respiratory and critical care medicine 176(12) (2007) 1185-1191.","DOI":"10.1164\/rccm.200704-571OC"},{"issue":"4","key":"10.1016\/j.bcp.2020.114112_b0445","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.chest.2019.10.053","article-title":"Characterization of Severe Asthma Worldwide: Data From the International Severe Asthma Registry","volume":"157","author":"Wang","year":"2020","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.bcp.2020.114112_b0450","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/ACI.0000000000000430","article-title":"Development of allergic sensitization and its relevance to paediatric asthma","volume":"18","author":"Oksel","year":"2018","journal-title":"Curr. Opin. Allergy Clin. Immunol"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295220303488?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295220303488?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:10:28Z","timestamp":1757769028000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295220303488"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":90,"alternative-id":["S0006295220303488"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2020.114112","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The management of severe asthma in 2020","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2020.114112","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114112"}}